Release date: 2016-09-08
Nowadays, China faces many problems such as the uneven distribution of medical resources and the overcrowding of large hospitals. To this end, there is an urgent need for more rapid and accurate diagnostic methods and equipment to promote "graded diagnosis and treatment." The point-of-care (POCT) technology in molecular diagnostics enables accurate and rapid disease diagnosis around the patient without the need for a dedicated laboratory. These characteristics make it a huge market for applications in primary care settings.
Kayudi is focused on the POCT field and is dedicated to the new genetic molecular diagnostic platform, which was established in 2009. Founder CEO Li Xiang is a master's degree in biophysics from the University of California, USA. He was named as a new star in Zhongguancun. The CTO Jesus Ching served as the former R&D director of Cepheid, the world's first on-site molecular diagnostics listed company. He has extensive industry experience.
In the field of POCT molecular diagnostics, the core product of Kayudi is the portable Mini8 real-time PCR instrument. This product was launched by Kayudi in 2013. Through a simple "one-step" method for nucleic acid-free molecular detection, Mini8 can achieve on-site popularization and rapid testing of the target gene, shortening the traditional 4-hour detection to 90 minutes or even 30 minutes. In 2015, Mini8 was widely used in epidemiological field tests, including Ebola, Zika, and Yellow fever in Africa, and became the first supplier of testing instruments in China to be included in the World Health Organization (WTO) list, as well as the first The on-site rapid screening platform cooperated by the National CDC has played a significant role in the entry and exit inspection of the epidemic.
In August 2016, Mini8 successfully obtained CFDA certification. Li Xiang told 36 氪, "The next step, Kayudi will plan to promote Mini8 in primary care, mainly for the dimethyl hospital in the prefecture-level city." Kayudi's genetic testing services mainly focus on maternal and child fields, products for infection Rapid screening of diseases, individualized medication guidance, intestinal microbiological monitoring of infants and young children. Li Xiang said that infantile intestinal microbiological monitoring is the focus of Kayudi. Kayudi will cooperate with the pediatrician Cui Yutao's Yu Xueyuan clinic to launch the “Million Chinese Intestinal Flora†testing program, which is expected to accurately diagnose children's diseases and nutritional metabolism through the detection of intestinal flora.
Compared to other companies that provide genetic testing services to hospitals, Kayudi's advantage is decentralization. Li Xiang said that domestic genetic testing companies generally collect medical samples from hospitals, collect samples from hospitals, and let professional technicians perform sample testing and produce results in medical laboratories. With the advantage of mini8's on-site inspection, Kayudi does not need to set up a medical clinic and hire technicians. Just put the mini8 in the hospital and use the simple one-step method to quickly obtain the test results, which greatly saves the test time. And human and material costs. On the other hand, if the Mini8 can't do complex testing on the spot, the Kayudi Medical Institute also provides another high-tech platform based on second-generation sequencing to enable patients to detect complex samples.
In addition to the Mini8, Kayudi will plan to launch its first domestic digital PCR instrument at the end of the year, focusing on the field of tumor liquid biopsy. Li Xiang introduced that digital PCR instruments are expensive, each of which is up to millions of dollars. Currently, only four companies in the world produce digital PCR products, namely Bole, Bio-Rad, Raindance and Thermo Fisher.
Currently, Kayudi's team is about 150 people and has three subsidiaries. Kayudi Biotech Yixing Co., Ltd. specializes in the production of instruments and testing reagents. Coyote Bioscience USA in the United States is responsible for the research and development of some of the company's cutting-edge products and some overseas sales. Kayudi Medical Laboratory Co., Ltd. undertakes medical institutions and personal testing services.
In terms of financing, Kayudi has received a 30-yuan A round of financing from Safran Asia in 2014. In 2015, it won the investment of 80,000 yuan by Arctic Light Ventures, Safran Asia and Lenovo Star. Regarding the C round of financing, Li Xiang said that it will start at the end of the year.
Source: 36æ°ª
Active Pharmaceutical Ingredients
Product categories of Active Pharmaceutical Ingredients, we are specialized manufacturer and distributor from China, we have the perfect after-sales service and technical support. Look forward to your cooperation!
Active Pharmaceutical,Extracted from Chicken Bile,CAS NO.:81-25-4, Active Pharmaceutical Ingredients
SINOCHEM PHARMACEUTICAL CO., LTD , https://www.sinochemnutrition.com